Are new variants of psoriasis therapy (IL‐17 inhibitors) safe?

Psoriasis is a chronic, recurrent, inflammatory, and proliferative skin disease. Its etiology has not yet been fully assessed, but undoubtedly it is a multifaceted disease. The key role in its pathomechanism is played by genetic, immunologic, and environmental factors and stress. If traditional meth...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology Vol. 58; no. 12; pp. 1360 - 1365
Main Authors: Wcisło‐Dziadecka, Dominika, Kaźmierczak, Agata, Grabarek, Beniamin, Zbiciak‐Nylec, Martyna, Brzezińska‐Wcisło, Ligia
Format: Journal Article
Language:English
Published: England Blackwell Publishing Ltd 01.12.2019
Subjects:
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Biological Products - administration & dosage
Biological Products - adverse effects
Candida - immunology
Candidiasis - chemically induced
Candidiasis - epidemiology
Candidiasis - immunology
Candidiasis - microbiology
Clinical trials
Clinical Trials, Phase III as Topic
Cyclosporins
Dermatologic Agents - administration & dosage
Dermatologic Agents - adverse effects
Environmental factors
Etanercept
Etiology
Genetic engineering
Humans
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Incidence
Infliximab
Inhibitors
Interleukin 17
Interleukin-17 - antagonists & inhibitors
Interleukin-17 - immunology
Interleukins
Keratinocytes
Literature reviews
Methotrexate
Monoclonal antibodies
Nasopharyngitis - chemically induced
Nasopharyngitis - epidemiology
Nasopharyngitis - immunology
Phosphodiesterase
Phototherapy
Psoriasis
Psoriasis - drug therapy
Psoriasis - immunology
Retinoids
Signs and symptoms
Skin diseases
Therapy
Treatment Outcome
Tumor necrosis factor-α
ISSN:0011-9059, 1365-4632, 1365-4632
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a chronic, recurrent, inflammatory, and proliferative skin disease. Its etiology has not yet been fully assessed, but undoubtedly it is a multifaceted disease. The key role in its pathomechanism is played by genetic, immunologic, and environmental factors and stress. If traditional methods of psoriasis treatment (phototherapy, methotrexate, retinoids, cyclosporine A) fail, we reach for the following biopharmaceuticals – infliximab, etanercept, adalimumab, or ustekinumab. However, genetic engineering progress discovers new possibilities – the pending clinical trials involve IL‐17, IL‐23 antagonists, PDE4 and ‐3 and ‐1. Psoriasis etiopathogenesis mainly involves the IL‐17A, IL‐17F, and IL‐17A/F subtypes, which affect the keratinocytes. The biological therapy molecularly oriented with the antagonists of interleukin 17 is based mainly on the influence onto the cytokine in the manner that prevents it from binding with the receptor. Three biopharmaceuticals are currently under third phase studies: two fully humanized antibodies neutralizing IL‐17 – ixekizumab and secukinumab, and one human monoclonal antibody, brodalumab. The below work will be devoted to the analysis of possible undesirable symptoms, which were observed during the studies. We will try to review the latest literature concerning the most important clinical trials conducted in many centers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0011-9059
1365-4632
1365-4632
DOI:10.1111/ijd.14509